Choose your language to see content specific to you

Published On

October 11, 2023

Categories
Other Case Studies
Key features and benefits  

For Brands

  • Improve adherence to nationally endorsed immunization programme
  • Access actionable insights that helped better tackle bad actors and provide useful data to law enforcement agency.
  • Directly engage patients to get additional data on suspicious products.

For Consumers 

  • Instant assurance with each scan.
  • Active involvement and collaboration with manufacturers to build a safe ecosystem for all

Overview

In 2019, the Hong Kong government investigated over 1,000 cases of multiple patients experiencing redness and swelling after receiving counterfeited human papillomavirus (HPV) vaccines. Around the same time, authentic vaccines were parallel imported to neighbouring countries where supply was scarce. These vaccines bypassed local regulatory checks and proper cold chain storage - thereby, threatening patient safety. This resulted in eroding trust in HPV vaccines and cast a shadow of doubt over the authenticity of cervical vaccines. In a 2022 eZTracker survey, 91% of Hong Kong consumers placed importance on verifying vaccines and medicine, but among them, more than half were not confident in how to carry out the actual verification.

Solutions

Real-time verification of product provenance and a suite of fraud investigation services

How it works:

  1. Track and trace the movement of every vaccine product unit through their unique data code
  2. Trigger an alert if an unrecognised code is scanned
  3. Allow consumers to provide further information to aid investigations
  4. Access fraud investigation dashboards to monitor blacklisted codes and track product movements across borders.

Results

https://eztracker.digiknowlogy.com/wp-content/uploads/2023/10/effective-fraud-investigation-frame.png

Thousands

of suspected counterfeit and diversion scans detected

  • Over 90 fraud investigation reports exported
  • Vaccine demand and confidence grew with CAGR of 29.8%

Share this case study
Choose your language to see content specific to you